With nearly decade-old bribery charges hanging over its head, Novartis has been eager to wriggle out of U.S. prosecutors’ crosshairs.…More
The FDA is expanding its private sector collaborations to advance its understanding of real world data and evidence. Does this…More
In a typical change of heart at England’s drug cost watchdog, Kisqali has won coverage for previously treated breast cancer—after…More
As the 2020 election revs up, candidates are again targeting drug prices, with tough action plans from two Democratic candidates…More
AbbVie is looking for a plaque psoriasis shakeup as its anti-TNF megablockbuster Humira faces a sales decline. The drugmaker hopes…More
The two companies developing drugs to desensitize children against peanut allergies, Aimmune Therapeutics and DBV Technologies, haven’t disclosed their pricing…More
With the feds sniffing around Indivior’s aggressive marketing of opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker.…More
Change of plans: Just one day before the Trump administration rule requiring pharma to put drug list prices in TV…More
Ionis and its RNAi drug Tegsedi got a head start with England’s NHS, putting the pressure on Alnylam’s rival med…More
It’s not uncommon for drugmakers to raise prices to start the year or to start the second half of each…More
